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ABSTRACT 
 
  Previous studies have shown that apigenin and naringenin (flavonoids) suppress 
colon carcinogenesis by inducing apoptosis and suppressing proliferation in rats. The 
goal of this thesis was to test the hypothesis that apigenin and naringenin affect 
colonocyte proliferation and apoptosis by regulating expression of genes involved in 
microbial recognition (TLR-2, TLR-4), short chain fatty acid transport (MCT-1), cell 
cycle (p21), and apoptosis (Bax, Bcl-2, Fas, Noxa) as well as to determine if the 
mechanism of action was p53 dependent. Scraped mucosa was obtained from rats which 
received diets (0.02% naringenin, 0.1% apigenin, or basal) for 10 wks and were treated 
with AOM. YAMC and mp53 YAMC cells were treated with apigenin (0.1, 1, and 10 
μM), naringenin (0.1, 1, 10, 25, and 50 μM), or estradiol (1 nM, positive control) for 96 
h at non-permissive conditions. In vivo, apigenin suppressed MCT-1 (p<0.03), Bax 
(p=0.05), and Fas (p<0.05) expression compared to the control diet; and both flavonoids 
suppressed p21 (p<0.02) and TLR-4 (p<0.01) expression. Diet did not affect expression 
of Bcl-2 or TLR-2. 1 μM or greater apigenin or naringenin treatment exhibited dose-
dependent decreases (p<0.005) in cell numbers compared to vehicle in YAMCs, while 
no differences were identified in the mp53 YAMCs except with the highest treatment 
concentrations (p< 0.0001). No differences in proliferation were observed with apigenin 
or naringenin in either cell line, except with 20 μM apigenin treatment (p< 0.0001). 
Apoptosis and gene expression data were inconclusive in vitro due to a lack of response 
in the positive control. Considering MCT-1 is a butyrate transporter and butyrate induces 
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colonocyte p21 expression, the suppression of p21 expression may be a MCT-1 
mediated effect. Reduction of MCT-1, p21, and TLR-4 expression by apigenin and 
naringenin suggests that these flavonoids may be able to reduce colon carcinogenesis 
through their influence on expression of genes involved in multiple pathways. The dose-
dependent reduction in cell number induced by apigenin and naringenin is in part p53-
mediated; however, the reduction in mp53 YAMC cells resulting from the greatest 
concentrations suggests alternate pathways can be induced. These reductions in cell 
number were not related to changes in proliferation. 
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CHAPTER I 
 INTRODUCTION  
 
 Cancer is second only to heart disease as the leading cause of death in the United 
States, accounting for nearly 1 in every 4 deaths. Cancer will most likely affect all 
Americans in some way or another during their lifetimes. The lifetime risk of developing 
cancer is 1 in 2 for men and 1 in 3 for women (1). According to the American Cancer 
Society, in 2014 it is expected that 585,720 Americans will die of cancer (1). 
Specifically, colon cancer is the third most common in the number of cancer cases and in 
the number of cancer related deaths for both men and women in the US, with an 
estimated 96,830 new colon cancer cases and 50,310 colorectal cancer deaths for 2014 
(1). Upon diagnosis, the 5 year relative survival rate for those diagnosed with colon 
cancer is 64% in the US (2). Beyond the personal impact that cancer will have on 
individuals in society, it is also a major public health issue in regard to the significant 
burden to society. The estimate for overall costs of cancer in 2009 [the last year that 
costs were calculated by the National Institutes of Health (NIH)] was $216.6 billion, 
$86.6 billion for direct medical costs and $130.0 billion for indirect mortality (cost of 
lost productivity due to death) (1). 
Although the incidence of colon cancer is high, it is predicted that 70% of 
colorectal cancers are preventable by changes in lifestyle and eating habits (3). It has 
been reported that diets containing elevated levels of fruits and vegetables are associated 
with decreased risk of colon cancer (4-8). Bioactive compounds from fruits and 
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vegetables and their role in colon cancer has been a focus of many studies in recent 
years. In our laboratory, grapefruit was shown to reduce aberrant crypt foci, the early 
neoplastic lesions of colon cancer (9). Grapefruit also increased colonocyte apoptosis, an 
important mechanism involved in removing damaged cells and decreased colonocyte 
proliferation (9). Further work demonstrated that apigenin and naringenin, two bioactive 
compounds found in grapefruit, are able to suppress colon carcinogenesis (10). The 
protection may have resulted, in part, because of the increase in apoptosis found in 
colonocytes lining the luminal surface and the suppression of proliferation. However, the 
mechanisms underlying these effects were not identified in those experiments. The 
experiments described in this thesis have extended the examination of those observations 
to elucidate the mechanisms involved in upregulating apoptosis and downregulating 
proliferation in colonocytes.  
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CHAPTER II 
 LITERATURE REVIEW  
 
Colon Cancer 
Cancer is a group of diseases resulting from uncontrolled cell growth. According 
to the multi-stage carcinogenesis model, cancer begins when a cell is initiated by 
exposure to a carcinogen that causes a DNA adduct (11). DNA adducts can lead to a 
tumor promoting DNA mutation. The initiated cell can undergo subsequent additional 
transformations that enable it to start forming a preneoplastic lesion, which may become 
a cancer (11). 
In order for an initiated cell to progress through these stages to cancer, certain 
functional changes must occur. These changes include insensitivity to anti-growth 
signals, self-sufficiency in growth signals, evasion of apoptosis, sustained angiogenesis, 
limitless replicative potential, and activation of tissue invasion and metastasis (12). 
Differential expression of oncogenes and tumor suppressor genes is known to be 
involved in the functional changes that occur in cells and contribute to cancer 
progression.  Oncogenes are genes that can lead to cancer as a result of genetic or 
epigenetic changes in either their coding region or regulatory sequences. They can cause 
cancer by increasing cell proliferation and survival and by causing cell dedifferentiation, 
where a differentiated cell reverts to an earlier developmental stage (13). Tumor 
suppressor genes are genes that inhibit cell proliferation and survival. Inactivation or 
mutation of tumor suppressor genes also can increase the risk of tumorigenesis (13). In 
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colon cancer, multiple functional changes must occur to transform a normal cell into a 
malignant cell. Changes in oncogenes and tumor suppressor genes help an initiated cell 
gain the functional changes required to progress to cancer and metastasis.  
One change that is necessary for tumor growth is the evasion of apoptosis, or 
programmed cell death (11-12). Two distinct signaling pathways can initiate apoptosis, 
the intrinsic and extrinsic pathways; and, the tumor suppressor gene p53 is involved in 
both pathways. In response to DNA damage, aberrant growth signals, or oxidative stress, 
p53 is activated and can subsequently trigger a wide array of physiological responses, 
including induction of apoptosis, initiation of DNA repair, and initiation of cellular 
senescence (14-15). Approximately 50% of colorectal carcinomas are associated with 
point mutations in p53, which are also correlated to an increase in disease severity (16-
18). Once p53 becomes activated, it can alter the expression of downstream apoptotic 
genes, including Bax and Noxa (upregulate apoptosis) and Bcl-2 (downregulates 
apoptosis). The extrinsic pathway involves death receptor proteins (such as Fas) found 
on the surface of the cell (19). These death receptors bind to their respective ligands, 
assembling a death-inducing signaling complex. Fas is a major death receptor expressed 
in the normal colonic crypt (20-21). Both the intrinsic and extrinsic pathways converge 
in the caspase cascades at caspase-3, -6, and -7, which are the executioner caspases. 
Although there is low frequency of apoptosis in the colon (less than one apoptotic cell 
per crypt column), it remains important in the case of cancer progression (22). When 
apoptosis is dysregulated, cells that have DNA damage can continue to survive, 
promoting carcinogenesis (12). 
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Another change that is important is the insensitivity to anti-growth signals. 
p21
WAF1/CIP-1
 is a downstream target of the p53 protein. The p21 protein inhibits cyclin 
dependent kinases (CDKs), which have a direct function in the transition between cell 
cycle phases, thus leading to cellular arrest (23). After p53 is activated as a result of 
DNA damage, p21 is upregulated through the AMP-activated protein kinase (AMPK) 
pathway (24). AMPK is involved in cellular energy balance as well as in regulation of 
proliferation and growth through the inhibition of the mTOR pathway and activation of 
p21 and p53 (24). This activation will lead to a decrease in proliferation, allowing the 
cell to correct the damage. p21 is not involved directly in cellular repair but allows 
cellular arrest so that the damage is not copied. One study revealed that loss of p21 
accelerated tumor growth in mice expressing a mutant form of p53 that cannot induce 
apoptosis but retains partial cell cycle regulation, revealing that p21 is a major factor of 
tumor protection by p53 (25). When cellular proliferation is dysregulated, mutations 
become fixed and can be replicated during cell divisions, leading to the promotion and 
progression of carcinogenesis.  
Beyond the traditional functional changes seen in cancer, the intestines are 
unique because of the direct interaction they have with the microflora and their 
metabolites. The fermentation of complex carbohydrates, such as dietary fiber, produces 
butyrate, a short chain fatty acid, which can modulate colon carcinogenesis progression 
(26-27). There is evidence that butyrate is capable of regulating changes in cell cycle, 
differentiation, and cell apoptosis (28-29). Specifically, butyrate has been shown to 
restore p21 expression to control levels following repression by azoxymethane (AOM), a 
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colon specific carcinogen (30). A possible mechanism of this restoration is epigenetic 
changes. In human skin cancer cells, Nandakumar et al. demonstrated that p21 
expression could be restored by suppressing DNA methylation and by decreasing histone 
deacetylase (HDAC) activity with treatment of green tea polyphenols (31). Additionally, 
there is evidence that combinations of DHA and butyrate promotes apoptosis in part by 
inducing methylation of the anti-apoptotic genes, including Bcl-2 promoter (32). 
Epigenetic changes may be related to the fact that butyrate is a direct energy source in 
healthy colonocytes but not in typical cancer cells. Because cancer cells exhibit the 
Warburg effect (a high rate of glycolysis and lactic acid fermentation), their preferred 
energy source is glucose instead of butyrate (33-34). As a consequence, cancerous 
colonocytes accumulate butyrate within the nucleus, where it acts as a HDAC inhibitor, 
causing epigenetic regulation of gene expression (26). Butyrate’s potential to cause 
epigenetic changes make it especially important in colon cancer prevention. 
Beyond their fermentation products, the microbial population within the colon 
can come into direct contact with the colon epithelium. Toll-like receptors (TLRs), 
found on colonocytes, allow the cell to recognize commensal- and pathogen-associated 
molecular patterns from the gut microbiota (35). Therefore, the cell surface TLRs play a 
role in the immune and barrier function of intestinal epithelial cells; for example TLR-4 
is important for the inflammatory response during injury (activating NF-kB and inducing 
expression of IL-1, -6 and -8), while TLR-2 is important for mucosal integrity (36-37). 
TLR-4 and TLR-2 specifically play vital roles in the response to lipopolysaccharides 
(LPS, large glycoproteins found on the outer membrane of Gram-negative bacteria) (38). 
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TLR-4 triggers both the MyD88- and TRIF-dependent pathways, while TLR-2 primarily 
signals the MyD88-dependent pathway. The MyD88 pathway ultimately results in the 
activation of NF-κB, leading to the induction of inflammatory mediators (39). 
Furthermore, enhanced inflammation is known to cause promoting and initiating events 
in carcinogenesis (11). The activation of NF-κB and subsequent inflammatory response 
related to changes in TLR expression and activation can lead to the promotion of colon 
carcinogenesis (35). 
Colon cancer can be influenced by many environmental factors. It is predicted 
that 70% of colorectal cancers are preventable by changes in lifestyle and eating habits 
(3). It has been demonstrated that various bioactive compounds in fruits and vegetables 
have the ability to suppress early neoplastic lesions of colon cancer (9-10, 40-41). A 
potential mechanism of action could be the ability of dietary components to influence the 
homeostasis of the colonic epithelium through altering signal transduction pathways and 
transcriptional regulation. 
 
Apigenin and Naringenin  
Polyphenols are bioactive phytochemicals that contain aromatic rings with 
reactive hydroxyl groups. Specifically, the polyphenols of interest, apigenin and 
naringenin, are flavonoids. There are seven subclasses of flavonoids; apigenin is part of 
the flavone subclass, while naringenin is a flavanone. Apigenin and naringenin are very 
similar to one another, possessing the same functional groups attached in the same 
places; however, they differ by one additional double bond found on the aromatic ring of 
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apigenin at the C2-C3 position. This double bond makes apigenin more planar than 
naringenin (Figure 1). Polyphenols typically have a low bioavailability, and therefore 
reach the colon, where they can interact with colonocytes and the colonic microbiota 
(42). 
 
Apigenin     Naringenin 
   
Figure 1. Structures of Apigenin and Naringenin. Apigenin and naringenin 
possess the same functional groups and differ in only one aromatic ring structure. 
Apigenin is a flavone, which has an additional double bond, compared to naringenin. 
Structures adapted from Liang et al. (43).   
 
 
 
Besides grapefruit, parsley, celery and chamomile tea contain apigenin, while 
oranges and tomatoes contain naringenin. The daily intake of flavonoids has been 
estimated to be as high as 0.5-1.0 g in the American diet (value refers to total flavonoid 
intake) (44); however, other reports predict a lower actual daily intake in some cultures, 
ranging from 1-9 mg (South African diet) to 75-81 mg (Scandinavian diet) (values 
mostly refer to five flavonoids) (45).  
In our laboratory, it has been demonstrated that apigenin and naringenin reduce 
the number of high multiplicity aberrant crypt foci (HMACF) in an AOM injected rat 
model (10). Aberrant crypt foci containing more than four crypts are referred to as 
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HMACF, and are correlated with subsequent formation of adenomas and 
adenocarcinomas (46-47). This protection may be due to the increased apoptosis on the 
luminal surface and decreased proliferation within the crypt. These phenotypic changes 
are likely downstream of alterations in transcription of genes in the p21 and caspase 
pathways as well as changes in the production of inflammatory mediators. Although the 
previous work in our lab identified no significant changes in the protein levels of Cox-2, 
an enzyme responsible for inflammatory mediators, or iNOS, a protein which can be 
induced to generate large amounts of nitric oxide involved in inhibiting the growth of 
invading microorganisms and neoplastic tissues (10), others have demonstrated changes 
in the expression of these genes with apigenin treatment (48-50). 
The chemoprotective ability of apigenin and naringenin may be related to p53 
expression and activity. McVean et al. demonstrated that apigenin treatment increased 
the half-life of p53 in mouse keratinocyte 308 cells, suggesting that apigenin may exert 
anti-tumorigenic activity by stimulating the p53 pathway (51). Moreover, Zheng et al. 
revealed that apigenin was able to induce apoptosis and G1 cell cycle arrest in cervical 
carcinoma cells, which was associated with increases in p53, p21, Bax, and Fas protein 
levels and reductions in Bcl-2 protein levels (52). Another study showed that apigenin 
caused induction of apoptosis in a human neuroblastoma cell line, but it did not change 
apoptosis in a corresponding mutant p53 expressing cell line (53). In that experiment, the 
increase in p53 protein levels upon apigenin treatment also led to an increase in protein 
expression of p21 and Bax in the human neuroblastoma cells but not in the mutated p53 
cell line (53). In addition to alterations in the gene and protein expression of p53, 
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changes in gene expression of the downstream targets may also occur with apigenin or 
naringenin treatment.  Park et al. showed that induction of apoptosis in human leukemia 
THP-1 cells treated with naringenin was in part due to downregulation of Bcl-2 and 
upregulation of Bax, resulting in activation of caspases (54). This induction of apoptosis 
was associated with the reduced activity of the PI3k/Akt pathway (54). Several other 
studies indicate that apigenin and naringenin work to activate the MAPK (ERK 1/2) 
pathway (55-57). Apigenin has also been demonstrated to inhibit the Noxa-induced 
phosphorylation of p38 MAPK, which is involved in the downregulation of the 
expression of matrix metalloproteinase-9 (MMP-9, can promote tumorigenesis through 
extracellular matrix remodeling and angiogenesis) (58). With these studies, there is 
marked evidence that apigenin and naringenin at least in part work through a p53-
dependent pathway, affecting the activation of the apoptotic as well as the proliferation 
pathways. 
In regards to cell cycle, Wang et al. reported a reversible induction of G2/M 
arrest by apigenin in three colon carcinoma cell lines (59). Apigenin induces G2/M cell 
cycle arrest, in part, due to increased p53 and p21 protein levels (60). Gupta et al. went 
further discovering an induction of p21 transcriptional upregulation in human prostate 
carcinoma cells (61). These studies indicate that cell cycle arrest and specifically 
increased expression of the p21 gene may explain, at least in part, apigenin’s ability to 
reduce carcinogenesis. 
Naringenin and apigenin may also impact apoptosis via changes in MCT-1 
activity and butyrate availability. Naringenin was shown to decrease the activity but not 
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the expression of MCT-1 in Caco-2 (human colon cancer) cells, blocking uptake of 
benzoic acid by MCT-1 (62). Cellular accumulation of naringenin revealed that the 
decreased transport was not due to naringenin being used as a substrate of MCT-1 (62). 
Both compounds were also shown to reduce the uptake of γ-hydroxybutyrate in human 
breast cancer cells (MDA-MB231) (59). Moreover, increased lactate uptake in HT-29 
(human colon cancer cells) with treatments of a flavone (the basic structure of apigenin) 
was associated with ROS production and ultimately apoptosis induction; but this 
apoptosis induction was significantly reduced by pCMBS, an MCT-1 inhibitor (63). 
These studies indicate that MCT-1 activity is altered in the presence of flavonoids and is 
related to apoptosis induction. In addition to MCT-1 activity, actual butyrate availability 
has been recognized to increase apoptosis. Butyrate has been shown to upregulate p21 
expression (30). According to Fan et al., butyrate-induced apoptosis was increased by 
Fas and FasL and was blocked by inhibitors of FasL and caspases (21). With this in 
mind, MCT-1 expression and activity appear to be relevant to apigenin and naringenin’s 
ability to reduce carcinogenesis, especially in regard to butyrate availability.  
 Beyond butyrate availability, the actual interaction of the microflora to the host 
can be impacted by the diet and can have an effect on disease states. TLRs allow 
communication between the colonic epithelium and the microbial population. One study 
showed that orange juice (a source of naringenin) prevented the elevated expression of 
IL-1β, TNFα, and TLR-4 and the induction of NF-κB binding, which was found in 
subjects given cream or glucose drinks in place of orange juice (except TLR-4, which 
was only elevated with cream drink consumption) (64). These same researchers also 
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showed that orange juice exerted a powerful inhibition of ROS generation (65). 
Moreover, luteolin, another flavonoid, suppressed the activation of TLR-4, blocking 
downstream target genes including TNFα and IL-6, in a mouse macrophage cell line (66-
67). Additionally, Youn et al. discovered that a polyphenol component in green tea was 
able to suppress MyD88- and TRIF-dependent TLR signaling pathways in a murine 
monocytic cell line and a human embryonic kidney cell line (68). These studies provide 
further evidence that flavonoids can reduce inflammation, which is a promoter of 
carcinogenesis. Parkar et al. even discovered that naringenin was able to inhibit specific 
bacteria from adhering to Caco-2 cells (69). If naringenin and apigenin have the ability 
to alter the expression of TLRs or the gut microecology, then the inflammatory response 
as well as butyrate availability may be impacted, affecting downstream initiation and 
promotion events as well as apoptotic pathways.  
Furthermore, apigenin and naringenin may have estrogenic effects. Estrogen has 
been shown to be protective against colon cancer (70-75). This is shown not only in the 
decreased incidence in pre-menopausal women compared to men but also in hormone 
replacement therapy (HRT) clinical studies (71, 73-75). Data from a collaborator’s 
laboratory have demonstrated that estradiol (E2) suppressed cell growth through 
induction of apoptosis in a non-transformed, non-malignant young adult mouse 
colonocyte primary cell line (YAMC bleo/neo) compared to a p53-null version of the 
same cells (YAMC mp53/neo) (76). Increased apoptotic activity along with a reduction 
in preneoplastic lesions was seen in ovariectomized wild-type mice treated with E2 
compared to wild-type control mice and the ERβ knockout mice receiving either 
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treatment (77). By binding with estrogen receptor beta (ERβ), E2 activity is reported to 
protect against colon carcinogenesis via apoptosis induction and activation of p53 (tumor 
suppressor gene) (76-77). Yet HRT has risks related to cardiovascular disease and other 
estrogen sensitive cancers related to ERα (breast and ovarian) and may not be an 
acceptable option for men (78). Therefore, research has been targeted at the potential of 
phytoestrogens to mimic the effects of estrogen on colon cancer risk without the 
associated dangers. Phytoestrogens are plant derived non-steroid phenols with similar 
physiological functions as estrogen. A diet rich in soy, which contains phytoestrogens 
such as genistein, has been associated with chemo-protective benefits and reduced colon 
cancer risk (79). In fact, genistein treatment of non-transformed YAMCs led to an 
increase in p53 transcriptional activity (80). Naringenin has been identified as an ERα 
antagonist but is able to bind to ERβ, whereas apigenin shows affinity to both estrogen 
receptors (81); however, the role of apigenin and naringenin as phytoestrogens in colon 
cancer prevention is not yet clear. One study has shown that sorghum phenolic extracts 
(which contained apigenin) had estrogenic activity and also induced apoptosis in 
nonmalignant YAMCs (82). To determine if apigenin and naringenin may have 
estrogenic effects, E2 was used as a positive control in vitro to induce apoptosis via 
upregulation of Bax and Noxa gene expression and downregulation of Bcl-2 gene 
expression 
The literature indicates that apigenin and naringenin can modulate several of 
these cellular perturbations that increase cancer risk, including promotion of cell cycle 
arrest and apoptosis. Furthermore, naringenin and other flavonoids have been reported to 
 14 
 
 
alter short chain fatty acid uptake by MCT-1 as well as inflammation regulated by TLR 
pathways. These changes appear to be related to transcriptional regulation by the 
flavonoids; therefore, this thesis has focused on understanding that regulation. Based on 
the mechanisms involved in the apoptotic and proliferation pathways within cancer 
development and research relating apigenin and naringenin to changes in gene 
expression or gene products within those pathways, several target genes were selected to 
measure expression levels. These include Bcl-2, Bax, Fas, and Noxa (involved in 
apoptosis regulation), p21 (cell cycle regulation), MCT-1 (short chain fatty acid 
transport), and TLR-2 and -4 (microbial recognition). 
 
Hypothesis 
We hypothesized that apigenin and naringenin lower the incidence of colonic 
preneoplastic lesions by regulating expression of genes involved in microbial 
recognition, short chain fatty acid transport, cell cycle, and apoptosis, especially those 
that may be p53 target genes.  
 
Specifically, our aims were: 
1. To determine the in vivo expression of Bcl-2, Bax, Fas, MCT-1, p21, TLR-2 and 
TLR-4 using scraped colon mucosa from rats fed apigenin, naringenin, or basal 
diets. 
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2. To determine the effects of apigenin and naringenin on conditionally 
immortalized (bleo/neo) and transformed (mp53/neo) YAMCs. Variables 
measured include: 
a. Cell number, proliferation, and apoptosis, and 
b. Gene expression of Bax, Bcl-2, p21, Noxa, and MCT-1. 
 16 
 
 
CHAPTER III 
 MATERIALS AND METHODS 
 
Experiment I—In Vivo Gene Expression 
Scraped Mucosa from Rats. Colon tissue samples were acquired from a previous 
study done in our laboratory (10). Male Sprague Dawley rats (21-d) received either 
basal, apigenin (0.1%), or naringenin (0.02%) diets for 10 wks (10 rats/diet group). All 
rats were injected twice with 15 mg AOM per kg body weight, spaced 1 wk apart. The 
first injection was given after 3 wks of experimental diets. Rats were terminated 6 wks 
after the last AOM injection and colon tissue was collected (Figure 2). The tissue used in 
the present study was scraped mucosa that had been homogenized in lysis buffer 
solution, flash frozen, and stored at -80°C (Figure 3).  
 
 
 
Figure 2. Timeline of Animal Study. Rats were acclimated for 5 d upon arrival 
and then stratified according to their body weights into 3 groups. Animals were given 
diets for 3 wks prior to the first AOM treatment. All rats were injected twice with AOM, 
spaced 1 wk apart. Rats were terminated 6 wks after the last AOM injection and colon 
tissues were collected. Figure from Leonardi (83). 
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Figure 3. Schematic Diagram of Rat Colon Sample Collections. RNA was 
collected from the section labeled scraped mucosa. Abbreviations: EtOH, ethanol; PFA, 
4% paraformaldehyde. Figure adapted from Leonardi (83). 
 
 
RNA Isolation from Scraped Mucosa. RNA was isolated from scraped colon 
mucosa using the RNAqueous kit (Ambion), according to kit protocol and based on the 
procedures used by Monk et at. (84). After isolation, RNA was immediately treated with 
the DNA-free kit (Ambion), according to kit protocol, to remove all remaining DNA. 
The concentration and quantity of the isolated RNA was determined using a Nanodrop. 
Quality of the isolated RNA was measured on an Agilent 2100 Bioanalyzer.  RNA 
integrity number (RIN) value of 10 indicates intact RNA, and a value of 8 and above is 
considered high quality RNA (85). We choose to use only RNA with a RIN value of 9 or 
higher for better and more consistent results in downstream experiments.  
 
Gene Expression Using RNA Isolated from Scraped Mucosa. Prior to 
completing reverse transcription (RT) and gene expression, a trial was performed to 
determine what concentration of RNA in the RT reactions would be optimal for analysis. 
Scraped Mucosa 
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It was determined that by using 150 ng of RNA the expression would be in the linear 
range of all target genes.  
After assuring that the isolated RNA was intact, RT reactions to prepare cDNA 
from the isolated total RNA were performed according to the procedures of Fan et al. 
(86), using SuperScript III Reverse Transcriptase with the addition of random hexamers. 
Minus RT reactions (water was used in place of SuperScript III) were used as the 
negative control. The cDNA was aliquoted into microcentrifuge tubes to decrease the 
amount of thawing and refreezing, which can damage cDNA.  
Expression of Bcl-2, Bax, Fas, p21, MCT-1, TLR-2, and TLR-4 was measured 
by real-time quantitative Reverse Transcription PCR (qRT-PCR) using TaqMan Gene 
Expression Master Mix and Taqman Primers (86). Each plate was set up with all 
samples plus two minus RT reactions in duplicate for the gene of interest.  A positive 
control gene (18S) for each sample and a minus RT reaction for 18S were also included. 
The real-time qPCR was completed under standard conditions using the FAM detector 
on an Applied Biosystems 7900HT Fast Real-Time PCR System for 40 cycles. 
 
Experiment II—In Vitro Effects 
 Cell Maintenance.  Young Adult Mouse Colonocytes (YAMCs), bleo/neo (non-
transformed) and mp53/neo (mutated p53 protein), were utilized for the in vitro 
experiments to assess whether apigenin or naringenin’s effect on apoptosis and 
proliferation is p53-mediated. YAMCs were supplied by Dr. Clinton Allred (Department 
of Nutrition and Food Science, Texas A&M University, College Station, TX). Cells 
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were maintained as previously described by Weige et al. (76). Briefly, YAMCs were 
cultured in RPMI 1640 media (Sigma-Aldrich), containing 10% (v/v) fetal bovine serum 
(FBS; HyClone), 1xITS-A (BD Biosciences), and 2.5 µg/ml gentamycin (GIBCO), and 
were maintained on rat tail collagen type 1 (BD Biosciences) coated plates at the 
permissive conditions of 33°C and 5% CO2 with 5 units interferon gamma (IFN-γ)/ml 
media (Roche) (76). Media was changed approximately three times per wk, and cells 
were split when they became nearly 100% confluent on the plate. YAMCs were only 
passaged for 60 d past the initial thaw date. All replicates of one type of experiment were 
conducted using cells from the same batch of thawed cells.   
 
 Apigenin and Naringenin Concentrations for Cell Culture. Based on the low 
bioavailability of apigenin and naringenin and the subsequent high concentration in the 
colon (42) and considering the percent of apigenin or naringenin in the rat diet, it was 
predicted that the concentrations of apigenin and naringenin within the rat colons in the 
in vivo study were 74.47 µM and 24.73 µM, respectively. This is the formula used for 
this calculation: 
Colon [flavonoid] = % flavonoid in diet X wt. of food intake (g) X (molecular wt. of 
flavonoid)
-1
 X 10
-6
 µM/M. 
 Based on the projected colon concentrations and other cell culture studies (52, 
54, 61, 87-88), a preliminary cell growth study was conducted with 25, 50, 100, and 200 
µM treatments of apigenin and naringenin. During this time, it was determined that 
treatment of 50 µM or higher apigenin and treatment of 200 µM naringenin to the non-
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transformed YAMCs was toxic to the cells. At 25 µM, apigenin was shown to lower cell 
number to approximately 10-15% of the vehicle. Therefore lower concentrations were 
tested, and the decision was made to treat cells with 0.1, 1, and 10 µM apigenin and 0.1, 
1, 10, 25, and 50 µM naringenin for the cell growth assay. Based on data in the cell 
growth assay, the concentrations of apigenin and naringenin that elicited reductions in 
cell number similar to estradiol were selected for proliferation, apoptosis, and in vitro 
gene expression analysis.  
 
Cell Growth Assay. YAMC bleo/neo and mp53/neo cells were split into charcoal 
dextran stripped FBS media in the presence of IFN-γ. After 2 d, cells were collected and 
counted using a hemocytometer. Approximately 15,000 cells were seeded in each well 
on a collagenized 6-well plate. Cells were kept in permissive conditions, 33°C, for 24 h, 
allowing them to adhere to the plate overnight. Cells were treated with media containing 
apigenin or naringenin for 96 h and were maintained at non-permissive conditions, 37°C, 
without the presence of INF-γ and with media changed every 48 h (Figure 4). 
Treatments included apigenin (0.1, 1, and 10 µM), naringenin (0.1, 1, 10, 25, and 50 
µM), estradiol (1 nM; positive control) and DMSO (vehicle; not exceeding 10% in the 
media). Because of the known effects seen in these cells on cell growth, apoptosis, and 
p53 target genes by estradiol treatment, estradiol was used as a positive control in our in 
vitro experiments (76). After 96 h of treatment, cells were collected and counted using a 
coulter counter (76). Three wells per treatment per experiment were used and five 
replicate experiments conducted. 
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Figure 4. Timeline of Cell Culture Experiments. YAMCs were acclimated for 
2 d in media stripped of hormones, including estrogen. The same number of cells was 
plated in each well. Cells were treated 24 h after plating and again 48 h post initial 
treatment. For proliferation experiments, BrdU was added 18 h prior to final assay. Cell 
number, proliferation, or apoptosis was measured at 96 h after initial treatment. For gene 
expression, RNA was collected after 24 h of treatment. Each run included 3 wells for 
each treatment group and at least 3 runs were conducted for each type of assay.  
 
 
 
Proliferation.  YAMC bleo/neo and mp53/neo cells were split into charcoal 
dextran stripped FBS media in the presence of IFN-γ. After 2 d, cells were collected and 
counted using a hemocytometer. Approximately 2,000 cells were seeded in each well on 
a collagenized 96-well plate. Cells were kept in permissive conditions for 24 h, allowing 
them to adhere to the plate overnight. Cells were treated for 96 h and media changed 
every 48 h (Figure 4). Treatments included 0.1 or 1 µM apigenin, 1 or 10 µM 
naringenin, 1 nM estradiol, and DMSO (vehicle). Estradiol was not shown to reduce 
proliferation in non-transformed YAMCs (80); therefore 20 µM apigenin was used as a 
positive control based on G1 cell cycle arrest and induction of p21 protein reported in 
human prostate carcinoma cells with this concentration of apigenin (61). After treatment, 
cells were maintained at non-permissive conditions, 39°C without the presence of INF-γ.  
At 78 h, Bromodeoxyuridine (BrdU), from the CalBiochem BrdU Cell Proliferation 
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Assay kit (Calboichem) was added; and cells were allowed to incubate for 18 h. BrdU, a 
synthetic analog of thymidine, can replace it during DNA synthesis and be measured to 
indicate cellular proliferation (80). BrdU was incorporated using the kit protocol and was 
based on the procedures used by Billimek (80), which includes measuring fluorescence 
on a TECAN Infinite M200 plate reader at wavelengths of 450 and 540 nm. Three wells 
per treatment per experiment were used and three replicate experiments conducted. 
 
Apoptosis. YAMC bleo/neo and mp53/neo cells were seeded in the same manner 
as the cell number assay. Cells were maintained under non-permissive conditions, 39°C, 
in charcoal-dextran stripped FBS media. Treatments included 0.1 or 1 µM apigenin, 1 or 
10 µM naringenin, 1 nM estradiol (positive control), and DMSO (vehicle). After 96 h of 
treatment, cells adherent to the plate and cells floating in the media were collected and 
lysed (Figure 4). Caspase activity was measured using EnzCheck Caspase-3 Assay Kit 
#2 (Molecular Probes), with various concentrations of Rhodamine 110 diluted in 1X 
reaction buffer used as standards and lysis binding solution used as a non-enzyme 
control (76). Fluorescence was measured on a TECAN Infinite M200 or SpectraMax 
Gemini EM plate reader (consistent between runs in each attempt) at wavelengths of 496 
and 520 nm at 15 min intervals from 30 min up to 1 h. Three wells per treatment per 
experiment were used and at least three replicate experiments conducted.  
 
Gene Expression. Approximately, 80,000 YAMC bleo/neo and mp53/neo cells 
were seeded in each well of a collagenized 6-well plate and maintained under non-
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permissive conditions, 39°C, in charcoal dextran stripped FBS media. Cells were grown 
for 72 h and treated during the final 24 h (Figure 4). Treatments included 0.1 or 1 µM 
apigenin, 1 or 10 µM naringenin, 1 nM estradiol, and DMSO (vehicle). There were three 
wells per treatment and three replicate experiments conducted. RNA was isolated using 
the Direct-zol™ RNA MiniPrep kit (Zymo Research), according to kit protocol. RNA 
was in-column DNase I treated. Immediately after isolation, the concentration of the 
isolated RNA was determined using a Nanodrop. Quality of the isolated RNA was 
measured on an Agilent 2100 Bioanalyzer. We chose to use RNA with a RIN value of 9 
or higher for better and more consistent results in downstream experiments, except for 
two samples that had RIN values of 8.7 and 8.9.  
Prior to completing reverse transcription (RT) and gene expression analysis, a 
trial was performed to determine what concentration of RNA in the RT reactions would 
be optimal for analysis. It was determined that by using 100 ng of RNA the expression 
would be in the linear range of all target genes.  
After assuring that the isolated RNA was intact, RT reactions to prepare cDNA 
from isolated total RNA were performed according to the procedures of Fan et al. (86), 
using SuperScript III Reverse Transcriptase with the addition of random hexamers. 
Minus RT reactions (water was used in place of SuperScript III) were used as the 
negative control. The cDNA was aliquoted into microcentrifuge tubes to decrease the 
amount of thawing and refreezing, which can damage cDNA.  
Expression of Bcl-2, Bax, p21, MCT-1, and Noxa was measured by real-time 
qRT-PCR using TaqMan Gene Expression Master Mix and Taqman Primers (86). Each 
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plate was set up with samples from two cell culture runs in duplicate plus a minus RT 
reaction from each RT run for the gene of interest.  A positive control gene (18S) was 
treated as a separate gene on its own plate due to limited space. The real-time qPCR was 
completed under standard conditions using the FAM detector on an Applied Biosystems 
7900HT Fast Real-Time PCR System for 40 cycles. 
 
Statistical Analyses 
All data are presented as means +/- SEM. Cell culture experiments were 
conducted in triplicate, as a minimum requirement. Gene expression data was 
transformed from Ct values to expression levels by the following formula: expression = 
2
40-Ct
. Expression values of genes of interest were normalized to 18S expression levels of 
matching samples. For in vivo gene expression, the average Ct value from corresponding 
18S samples on all plates was used to calculate 18S expression, which was then used to 
normalize data. In vivo gene expression analysis was completed using Welch’s t-test and 
Shapiro-Wilk normality test in R. Analysis of in vitro data was performed using a one 
way ANOVA, using the generalized linear model in SAS. Differences with p <0.05 were 
considered significant. Additionally, normality of cell number, proliferation, apoptosis 
and in vitro gene expression data was confirmed by using the D’Agostino-Pearson 
normality test in GraphPad Prism
®
.  
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CHAPTER IV 
 RESULTS 
 
Experiment I—In Vivo Results  
Previous work in our lab showed that apigenin and naringenin suppress the 
preneoplastic lesions of colon cancer by inducing apoptosis and suppressing 
proliferation in rats (10). Therefore, the goal of the first experiment was to identify how 
apigenin and naringenin affect proliferation and apoptosis by measuring gene expression 
of selected genes involved in these two pathways. 
 
Apigenin and Naringenin Alter Gene Expression of Bax, Fas, MCT-1, p21, 
and TLR-4 but Not Bcl-2 or TLR-2. To determine if apigenin and naringenin altered 
proliferation and apoptosis through changes in gene expression related to microbial 
recognition (TLR-2, TLR-4), short chain fatty acid transport (MCT-1), cell cycle (p21), 
or apoptosis (Bax, Bcl-2, Fas), real-time qRT-PCR was performed on colonic mucosa 
from rats fed diets of apigenin and naringenin compared to the basal (control) diet. 
Apigenin suppressed (p=0.023) expression of MCT-1, a butyrate transporter, with 
naringenin leading to an intermediate suppression which approached a significant 
difference (p=0.061) from the basal diet (Figure 5). Additionally, apigenin reduced 
expression of pro-apoptotic genes Bax (p=0.05, Figure 6) and Fas (p=0.043, Figure 7). 
Furthermore, apigenin and naringenin suppressed (p<0.02) p21 expression, which is 
involved with cell cycle arrest (Figure 8). Expression of TLR-4, which is important in 
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the barrier function of the colon and in mediating inflammatory responses, also was 
suppressed by apigenin and naringenin (p<0.01) (Figure 9). Apigenin and naringenin 
diets did not significantly alter the expression of Bcl-2 or TLR-2 relative to the basal diet 
(Table 1).  
 
  
 
Figure 5. Experimental Diets Decrease MCT-1 Expression. Apigenin 
suppressed (p=0.023) MCT-1 expression (butyrate transporter) compared to basal, 
whereas naringenin only tended to suppress (p=0.061) expression. Values are means +/- 
SEM, n = 10 rats/group. Expression level normalized with 18S expression. 
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Figure 6. Experimental Diets Decrease Bax Expression. Apigenin suppressed 
(p=0.05) Bax expression (pro-apoptotic gene) compared to basal, while naringenin 
tended to suppress (p=0.085) expression Values are means +/- SEM, n = 10 rats/group. 
Expression level normalized with 18S expression. 
 
 
 
 
 
Figure 7. Experimental Diets Decrease Fas Expression. Apigenin suppressed 
(p=0.043) Fas expression (pro-apoptotic gene) compared to basal, while naringenin 
tended to suppress (p=0.152) expression. Values are means +/- SEM, n = 10 rats/group. 
Expression level normalized with 18S expression. 
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Figure 8. Experimental Diets Decrease p21 Expression. Apigenin and 
naringenin both suppressed p21 expression (cell cycle regulation) (p<0.02). Values are 
means +/- SEM, n = 10 rats/group. Expression level normalized with 18S expression. 
 
 
 
 
 
Figure 9. Experimental Diets Decrease TLR-4 Expression. Apigenin and 
naringenin suppressed TLR-4 expression (microbial recognition and promoter of 
proliferation) (p<0.01). Values are means +/- SEM, n = 10 rats/group. Expression level 
normalized with 18S expression. 
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TABLE 1 
Effect of Experimental Diets on Expression of Target Genes.
1
 
 
Target Genes 
Diet Group Bax Bcl-2 Fas MCT-1 p21 TLR-2 TLR-4 
Basal 7.344
a
 29.166
a
 3.275
a
 1.660
a
 5.449
a
 1.307
a
 12.120
a
 
Apigenin 4.476
b
 23.607
a
 2.059
b
 0.807
b
 3.036
b
 0.948
a
  6.296
b
 
Naringenin 4.790
a,b
 21.611
a
 2.398
a,b
 1.138
a,b
 3.464
b
 0.953
a
  7.553
b
 
SEM 0.501  1.594 0.208 0.125 0.392 0.079  0.699 
1
Values are given as means +/- SEM, n=10 rats/group. Expression level normalized with 
18S expression. Means in a column without a common letter differ significantly 
(p<0.05). 
 
Experiment II—In Vitro Results 
The results from the in vivo gene expression experiment identified some potential 
mechanisms by which apigenin and naringenin may suppress proliferation and promote 
apoptosis; however, questions remained, especially whether the chemoprevention 
induced by apigenin and naringenin was p53-mediated. Therefore, the second part of 
these investigations was conducted to determine not only the mechanisms involved in 
chemoprotection induced by apigenin and naringenin using controlled cell culture 
conditions but also to determine if the effects were p53 dependent. Using non-
transformed YAMCs compared to p53 null YAMCs allowed us to investigate both of 
these aims. 
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Apigenin and Naringenin Inhibit Non-Transformed Cell Growth but Not 
Mutated p53 Cell Growth. We measured the effects of apigenin and naringenin 
treatment on cell growth in non-transformed and mutated p53 YAMCs at non-permissive 
conditions (37°C). YAMC cells treated with 1 μM or greater apigenin or naringenin 
exhibited dose-dependent decreases (p<0.005) in cell numbers compared to cells treated 
with the vehicle (DMSO) (Figure 10A). No differences in cell number were identified in 
the mp53 YAMC cells, except with the highest concentration of apigenin and naringenin 
(p< 0.0001) (Figure 10B). These data demonstrate an inhibitory effect on cell growth in 
non-transformed cells but not p53 null cells except with a higher concentration. This 
signifies that whatever mechanisms are involved in reducing cell number with lower 
concentrations of apigenin and naringenin are in part p53-mediated.  
 
Apigenin and Naringenin Do Not Suppress Proliferation in Non-Transformed 
or Mutated p53 Colonocytes. To determine the mechanism by which apigenin and 
naringenin inhibit cell numbers, we first determined their impact on proliferation in non-
permissive conditions (39°C). No differences in proliferation were observed with 
apigenin or naringenin treatment in either cell line compared to the vehicle, except with 
20 μM apigenin (p< 0.0001) (Figure 11), indicating suppression of cell number in the 
non-transformed YAMCs is not due to a reduction in proliferation.  
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Figure 10. Experimental Treatments Decrease Cell Number in Non-
Transformed but Not Mutated p53 YAMCs. A) Non-transformed YAMCs treated 
with 1 μM or greater apigenin or naringenin exhibited dose-dependent decreases 
(p<0.005) in cell numbers compared to DMSO. B) The only significant differences seen 
between treatment groups compared to the vehicle treated mp53 YAMCs were with 10 
µM apigenin and 50 µM naringenin treatments (p<0.0001). Values are means +/- SEM, 
n = 15 wells/group (5 runs with 3 replicates each).  
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Apigenin and Naringenin Do Not Induce Apoptosis in Mutated p53 
Colonocytes. After discovering that apigenin and naringenin did not inhibit cell number 
via an inhibition of proliferation, we examined their effect on apoptosis in non-
permissive conditions (39°C). No differences were observed with treatment of apigenin 
or naringenin in either cell line compared to vehicle, even with estradiol treatment 
(Figure 12B). We have attempted (with multiple runs per attempt) to collect the 
apoptosis data for the bleo/neo YAMCs. In three of those attempts, there was a high rate 
of variability within treatment groups per run and inconsistent data between those runs; 
the attempt with the least variability is shown in Figure 12A. In addition to those 
problems, there was a lack of response in the positive control for all attempts, raising 
questions of the validity of the caspase data in the non-transformed YAMCs.  
 
Apigenin and Naringenin Affect Gene Expression of p21, MCT-1, or Noxa in 
Colonocytes. Even though the reduced cell number in the non-transformed YAMCs was 
not associated with suppressed proliferation or induction in apoptosis, we were still 
interested in exploring if any changes in gene expression were occurring with apigenin 
or naringenin treatment. In the non-transformed YAMCs, no significant differences were 
seen between any of the treatment groups for Bax, Bcl-2, Noxa, or MCT-1 expression 
(Table 2). We did note an increased expression of p21 with 1 µM naringenin treatment 
compared to DMSO, estradiol, and 0.1 and 1 µM apigenin treatments, while expression 
in cells treated with 10 µM naringenin trended up as well. 
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Figure 11. Experimental Treatments Do Not Alter Proliferation. No 
significant differences in proliferation were observed with treatments of apigenin or 
naringenin in the non-transformed (A) or mutated p53 (B) YAMCs, except with the 20 
µM apigenin treatment (p< 0.0001). Values are means +/- SEM, n = 9 wells/group (3 
runs with 3 replicates each).  
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Figure 12. Experimental Treatments Do Not Alter Apoptosis. No significant 
differences in apoptosis were observed with treatments of apigenin or naringenin in the 
non-transformed (A) or mutated p53 (B) YAMCs. Values are means expressed as fold 
change compared to vehicle +/- SEM. For non-transformed YAMCs, n=15 wells/group, 
(5 runs with 3 replicates each). For mp53 YAMCs, n = 9 wells/group (3 runs with 3 
replicates each).  
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For the mutated p53 YAMCs, there were outliers which correlated with different 
days on which RT reactions were performed. To preclude those data points from 
preventing us from identifying possible differences within the data, analysis removing 
those data points was used to determine significant differences. There were no 
significant differences seen in the expression of Bax, Bcl-2, or p21 between any of the 
treatment groups (Table 3), indicating that the reductions in cell number were not 
mediated through a p53 pathway involving these genes. MCT-1 expression was 
decreased with 1 µM naringenin compared to DMSO and 10 µM naringenin. 
Additionally, 1 µM naringenin also increased the expression of Noxa compared to 1 µM 
apigenin. Treatment of 10 µM naringenin also elicited an increase in Noxa expression 
compared to DMSO, E2, and 1 µM Apigenin. This indicates one possible mechanism for 
how the 50 µM naringenin treatment reduced cell number in the cell growth assay is via 
an increase in expression of Noxa, a pro-apoptotic gene. 
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TABLE 2 
Effect of Experimental Treatments on Expression of Target Genes 
in Non-Transformed YAMCs.
1
 
 
Target Genes 
Treatments Bax Bcl-2 Noxa MCT-1 p21 
DMSO 10.658
a
 12.567
a
 5.679
a
 18.533
a
 20.976
a
 
E2 10.572
a
 13.059
a
 5.479
a
 18.472
a
 19.410
a
 
0.1 µM Apigenin 10.436
a
 13.246
a
 5.470
a
 17.249
a
 19.561
a
 
1 µM Apigenin 10.439
a
 13.531
a
 6.011
a
 18.282
a
 21.027
a
 
1 µM Naringenin 12.437
a
 16.488
a
 6.150
a
 21.881
a
 26.683
b
 
10 µM Naringenin 11.083
a
 14.024
a
 5.762
a
 17.880
a
 22.556
a,b
 
SEM   1.450   2.406 0.579   2.671   1.987 
1
Values are given as means +/- SEM, n=9 wells/group. Expression level normalized with 
18S expression. Means in a column without a common letter differ significantly 
(p<0.05). 
  
 
 
TABLE 3 
Effect of Experimental Treatments on Expression of Target Genes  
in Mutated p53 YAMCs.
1 
 
Target Genes 
Treatments Bax Bcl-2 Noxa MCT-1 p21 
DMSO 7.550
a
 19.283
a
 2.915
a,b
 29.519
a
 17.758
a
 
E2 6.978
a
 20.569
a
 2.892
a,b
 26.365
a,b
 16.027
a
 
0.1 µM Apigenin 6.729
a
 21.313
a
 3.103
a,b,c
 25.189
a,b
 17.044
a
 
1 µM Apigenin 7.084
a
 16.585
a
 2.820
a
 24.724
a,b
 16.453
a
 
1 µM Naringenin 7.363
a
 20.237
a
 3.262
b,c
 22.024
b
 16.499
a
 
10 µM Naringenin 7.932
a
 18.331
a
 3.377
c
 28.665
a
 18.001
a
 
SEM 0.492   1.858 0.159   2.313   0.948 
1
Values are given as means +/- SEM, n=9 wells/group; however, a few outliers were 
removed. Expression level normalized with 18S expression. Means in a column without 
a common letter differ significantly (p<0.05). 
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CHAPTER V 
DISCUSSION 
 
The work described in this thesis was a two part study. The purpose of the first 
part of these experiments was to investigate the mechanisms involved in the reduced 
high multiplicity aberrant crypt foci, HMACF, reduced proliferation, and increased 
apoptosis seen in a previous in vivo study in our laboratory (10). Using real-time qRT-
PCR, it was determined that apigenin and naringenin were able to reduce the expression 
of Bax and Noxa (apoptosis), MCT-1 (short chain fatty acid transport), p21 (cell cycle 
regulation), and TLR-4 (microbial recognition). No change was seen in the expression of 
Bcl-2 or TLR-2. 
Several studies have reported an anti-proliferative effect with treatment of 
apigenin and naringenin and have related this to a reduction in p21 protein expression 
(52-53, 60-61, 89). Although there was a reduction in proliferation seen with animals fed 
apigenin or naringenin diets compared to the basal diet, this change contradicts the 
expected increase in p21 expression. We believe that the decrease in p21 expression is a 
result of the reduction in MCT-1 expression. Though, there is not research supporting a 
direct link to MCT-1 activity and expression to p21 expression, butyrate has been shown 
to upregulate p21 expression (30). Additionally, Hu et al. showed that butyrate treatment 
decreased HCT-116 (colon cancer cells) proliferation, which was associated with an 
increase in both p21 protein and mRNA expression (90). As mentioned in the literature 
review, butyrate has the potential to reduce tumorigenesis via epigenetic modulations 
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(26, 32). Considering that there was a protection against preneoplastic lesions, the 
reduction in MCT-1 expression is also opposite of what we expected. There is, however, 
evidence that supports polyphenols interfering with butyrate’s chemoprotective abilities. 
One study showed that green tea phenolic compounds impaired butyrate’s entry into the 
cell via interruption of the MCT-1 localization within lipid rafts (91). Conversely, 
another study demonstrated that a butyrate-rich colonic microenvironment may select for 
cancer cells that can metabolize butyrate, which tend to be more aggressive (92). Though 
we did not relate the increased apoptosis and reduced proliferation seen in animals fed 
apigenin or naringenin to an increase in p21, we did discover that these compounds may 
be interfering with the butyrate availability within the colonocytes via a reduction in 
MCT-1 expression, thus reducing p21 expression instead. Perhaps, the reduction in 
MCT-1 expression with apigenin and naringenin may be beneficial depending on 
whether the environment has selected for the more aggressive tumor cells that are able to 
utilize butyrate as an energy source. 
On the other hand, changes in in vivo TLR-4 expression are consistent with our 
hypothesis that apigenin and naringenin’s chemoprotection may be due to transcriptional 
regulation of this gene. Dou et al. (93) revealed that naringenin was able to reduce the 
severity of inflammation in dextran sulfate sodium (DSS)-induced murine colitis, 
resulting in downregulation of pro-inflammatory mediators. These changes where 
associated with lower TLR-4 protein and mRNA expressions and lower phospho-NF-κB 
p65 protein expression (93). Additionally, apigenin and genistein have both been shown 
to have anti-inflammatory effects via suppression of TLR-4 and NF-κB activity in LPS-
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induced models, reducing pro-inflammatory cytokine production (94-95). Specifically, 
apigenin was able to suppress p65 phosphorylation (95). With this understanding, it 
appears that apigenin and naringenin may be chemoprotective due to reduction in TLR-4 
expression and inhibition of the TLR-4/ NF-κB pathway.  
It is interesting that the expressions of the selected pro-apoptotic genes were 
reduced by apigenin and that the anti-apoptotic gene was unaffected by both flavonoids. 
This is contradictory to literature that shows increased pro-apoptotic gene or protein 
expression and reduced anti-apoptotic gene and protein expression (52-54). One 
possibility for these unexpected results is that, since the apoptosis was only seen at the 
luminal surface, the proportion of apoptotic cells on the luminal surface to the non-
apoptotic cells within the crypt washed out any possible detectable effect. Additionally, 
other cells, most likely from the lamina propria, may have also been collected during 
scraping. Furthermore, it may indicate that other genes upstream or downstream within 
the apoptotic pathways are transcriptionally regulated instead to increase apoptosis. For 
example, apigenin and naringenin have been demonstrated to modify p53 protein and 
gene expression as well as activate the MAPK/ERK 1/2 pathway (51-52, 54-57, 60). 
Though we did base our gene selection on research suggesting possible regulation via 
those genes, utilizing an apoptosis PCR array may have been a more constructive 
approach to understanding how apigenin and naringenin increased apoptosis. 
Additionally, since there were unexpected changes seen in the transcriptional regulation 
of several target genes, it would be illuminating to measure protein expression of 
 40 
 
 
enzymes related to apoptosis and cell cycle arrest to determine possible translational 
regulation.  
The estimated concentration of apigenin and naringenin that decreased the 
number of preneoplastic lesions in vivo varied from the concentration that reduced cell 
number in vivo. This may be due to in vivo interactions between the microbiota and the 
flavonoids of interest. Probable changes in the colon microbiota by apigenin and 
naringenin are reflected by changes in the microbial pattern recognition receptor TLR-4 
and the butyrate transporter MCT-1. Polyphenols have been reported to modify the gut 
microbiome (69, 96). In one study, polyphenols including chlorogenic acid, caffeic acid, 
and quercetin were shown to stimulate Bifidobacteria and decrease the ratio of 
Firmicutes to Bacteriodes (96). Conversely, apigenin and naringenin are also able to be 
biotransformed by gut bacteria. Rechner et al. (97) showed that naringin and naringenin 
along with other polyphenols have multiple degradation products. That degradation can 
depend on flavonoid concentration, individual microflora composition, and specific 
flavonoid structural differences (97). Furthermore, gut microbial metabolism of 
polyphenols from black tea and red wine or grape juice was demonstrated to be source 
and colon region specific (98). Shifts in the colon microbiome as well as modifications 
(increasing bioavailability) or metabolism (producing additional bioactive metabolites) 
of apigenin and naringenin by colonic bacteria may explain the differences in 
concentration sensitivity between the in vivo and in vitro studies. 
The second part of these investigations was to determine not only the 
mechanisms involved in chemoprotection induced by apigenin and naringenin using 
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controlled cell culture conditions but also to determine if the effects were p53 dependent. 
Additionally, it was of interest to compare changes to those resulting from estradiol 
treatment in order to identify if they have similar effects. 
In vitro, it was determined that a dose dependent decrease in cell number 
occurred with apigenin and naringenin treatment in the non-transformed YAMCs but not 
in their counterparts, the mutated p53 YAMCs, except at the highest concentration 
tested. These data substantiate the conclusions from the previous in vivo study that 
apigenin and naringenin may protect against colon cancer (10). Additionally, it is clear 
that the dose-dependent reduction in cell number by apigenin and naringenin is at least 
in part p53-mediated, especially at lower concentrations. This is consistent with other 
research that indicates that apigenin and naringenin can stimulate the p53 response 
pathway (51-53, 60). It was also determined that concentrations of 0.1 and 1 µM 
apigenin and 1 and 10 µM naringenin elicit an effect similar to estradiol, which has 
proven to reduce the number of preneoplastic lesions (77). The reduction of cell numbers 
in mp53 YAMCs resulting from the greatest concentrations of apigenin and naringenin 
treatments suggests alternate pathways can be induced by these flavonoids with a high 
threshold value. Gene expression analysis indicated that naringenin was able to induce 
expression of Noxa, a pro-apoptotic gene, compared to vehicle treated mp53 YAMCs.  
The effect on cell number is not linked directly to suppression of colonocyte 
proliferation in either p53 competent or mutant colonocytes. This does not support the 
reduction in proliferation documented in vivo (10), indicating that changes in 
proliferation may only be seen after exposure to a carcinogen. However, it does 
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correspond with previous studies where estradiol treatment in bleo/neo and mp53 
YAMCs do not reduce proliferation (76, 80). Moreover, treatment of 1 µM naringenin 
did significantly increase expression of p21 in the non-transformed YAMCs, with 10 
µM naringenin treatment trending up as well. This effect was not seen in the p53 null 
YAMCs. This may indicate that naringenin, at a higher concentration, may induce cell 
cycle arrest. 
Furthermore, there was no significant change in apoptosis with treatment of 
apigenin or naringenin in either non-transformed or p53 null YAMCs. The lack of 
change in the mutated p53 YAMCs is consistent with previous estradiol treatment of 
these cells (76, 80) as well as with literature indicating that these flavonoids act via a 
p53-mediated pathway (51-53, 60). However in the non-transformed YAMCs, apoptosis 
measurements were inconclusive due to the lack of induction with the positive control 
(estradiol). There were multiple attempts to collect the apoptosis data in the bleo/neo 
YAMCs, including an alternate assay. In most of those attempts, there was a high rate of 
variability within treatment groups per run and inconsistent data between those runs. The 
issues could not be resolved within the timeframe of this thesis; however, several factors 
may be involved. One concern was the change in non-permissive temperatures between 
the cell number assays and the other in vitro experiments. There is conflicting literature 
on what temperature is most appropriate as a non-permissive condition, ranging from 
37° to 39.5°C (76, 99-102). The temperature change was made due to evidence 
indicating that 39°C was the more appropriate non-permissive condition for the bleo/neo 
YAMCs, although a collaborator’s lab had used 37°C in the past (76). A change in 
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temperature could possibly have caused a loss in sensitivity and therefore a 
diminishment in the effect expected, but this is unlikely due to evidence showing 
reduced apoptosis via estradiol treatment at both temperatures (76, 80). Another issue is 
that these cells are highly sensitive based on reports from the donor. One example of this 
is that the non-transformed YAMCs are unable to be transported on dry ice. It may have 
been beneficial to use a less sensitive YAMC line with a corresponding p53 null cell 
line. Yang et al. (82) demonstrated an induction in apoptosis in less primary YAMCs 
with sorghum phenolic compounds and estradiol. However, the unique opportunity of 
using a primary cell to determine chemoprotective abilities would be lost. Another 
limitation is the fact that the cells are treated for 96 hours with media changed after 48 
hours. This could select for the more hardy cells that may not be sensitive or affected by 
the various treatments, similar to the idea that a butyrate-rich environment may select for 
more aggressive tumor cells (92). Though in the past it has not been necessary to 
normalize data to cell number in order to identify an induction in apoptosis with 
estradiol treatment, making this adjustment would provide a better apoptotic index.  
Similar to the apoptosis assays, the in vitro gene expression data was also 
inconclusive due to the lack of response of the positive control. Estradiol has been 
shown to induce expression of Bax and Noxa while reducing expression of Bcl-2 in 
bleo/neo YAMCs (76). As mentioned earlier, there was an increase in Noxa expression 
with naringenin treatments in the p53 null YAMCs. This suggests that one possible 
mechanism of how 50 µM naringenin treatment reduced cell number in mp53 YAMCs is 
via an increase in Noxa expression. Additionally, the fact that 1 µM naringenin 
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treatment led to a reduction in MCT-1 expression in the mp53 YAMCs confirms the 
change seen in vivo. Further investigation would be valuable to reassess the apoptosis 
induction and various gene expressions in non-transformed YAMCs treated with 
apigenin and naringenin.  
Overall the purpose of these experiments was to determine how apigenin and 
naringenin may decrease risk of colon carcinogenesis, specifically in the early stages, by 
first determining the mechanisms of apigenin and naringenin in vivo and then by further 
testing our hypothesis in vitro. 
In vivo, the increased apoptosis and reduced proliferation with apigenin and 
naringenin diets seen in a previous in vivo experiment were not related to an increase in 
p21 expression. However, we did discover that these flavonoids may interfere with the 
butyrate availability within the colonocytes, thus reducing p21 expression instead. This 
reduction in MCT-1 expression may help prevent against selection for the more 
aggressive tumor cells that are able to utilize butyrate as an energy source. Additionally, 
the reduced expression of TLR-4 suggests that apigenin and naringenin are able to 
modulate the inflammatory response, which promotes carcinogenesis, via the MyD88 
pathway that ultimately activates NF-κB. These changes may have contributed to 
apoptosis promotion and proliferation suppression to prevent preneoplastic lesions. 
In vitro, the dose-dependent reduction in cell number by apigenin and naringenin 
treatment in non-transformed but not p53 null YAMCs supports the previous in vivo 
conclusion that these flavonoids may be chemoprotective. This also indicates that the 
mechanism of action is at least in part p53-mediated. However, unlike the in vivo study, 
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the reduced cell number was unrelated to a reduction in proliferation. Additionally, the 
apoptosis and gene expression data were inconclusive for the non-transformed YAMCs. 
For the mutated p53 YAMCs, there was an increase in Noxa with naringenin treatment 
but not a corresponding induction in apoptosis. Additionally, 1 µM naringenin 
significantly reduced expression of MCT-1, supporting the in vivo analyses. Though 
more research is necessary to determine the specific mechanisms that reduced the cell 
number with apigenin and naringenin treatment, it appears to be in part p53-mediated. 
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CHAPTER VI 
SUMMARY AND CONCLUSIONS 
 
Previous work in our lab showed that rats injected with AOM had a lower 
incidence of HMACF, a preneoplastic lesion of the colon, when fed diets containing 
apigenin and naringenin compared to the basal diet. This chemoprotection was related to 
an increase in apoptosis at the luminal surface and a reduction in proliferation of 
colonocytes. The work in this thesis continued exploring the mechanisms involved in 
this protection. We found that apigenin and naringenin treatment of these animals led to 
a decrease in the gene expressions of Bax, Fas, MCT-1, p21, and TLR-4. There, 
however, was no significant change in Bcl-2 or TLR-2 gene expression. Suppressed 
expression of Bax and Fas by apigenin was contradictory to expected results. Since the 
increased apoptosis in the previous in vivo study was only seen at the luminal surface, 
we believe that the ratio of apoptotic cells from the luminal surface to the non-apoptotic 
cells within the crypt may have washed out any detectable increase in the expression of 
these genes. Additionally, other genes may be involved that we did not measure. The 
reduced proliferation with apigenin and naringenin diets seen in the previous in vivo 
study was not related to an increase in p21 expression. Yet, the discovery that these 
flavonoids may interfere with the butyrate availability within colonocytes via a reduction 
in MCT-1 expression explains why p21 expression is reduced instead. Additionally, 
suppression of TLR-4 expression alludes to the ability that apigenin and naringenin can 
downregulate the inflammatory response related to the MyD88/NF-κB pathway. These 
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data suggest that changes in transcriptional regulation are able to reduce the risk of 
carcinogenesis. 
In vitro, we discovered a dose dependent decrease in cell number of non-
transformed YAMCs with treatment of apigenin and naringenin but not in YAMCs with 
a mutated p53. Further work showed that this cell number reduction was not related to 
changes in proliferation. We attempted to connect the cell number decrease with 
apoptosis and related gene expression; however, the data was inconclusive and 
unreliable due to a lack of effect in the positive control. We believe that a possible cause 
is poor cell state related to the highly sensitive nature of primary cells. Due to the dose-
dependent reduction in non-transformed cell number but not mutated p53 cell number, 
we did conclude that the effects of apigenin and naringenin are in part p53-mediated. 
The reduction of cell numbers in mp53 YAMC cells resulting from the greatest 
concentrations suggests alternate pathways can be induced by these flavonoids at higher 
concentrations. Further investigation would be valuable to reassess the apoptosis 
induction and various gene expressions in YAMCs treated with apigenin and naringenin.   
 Research involving bioactive compounds is a field that deserves continued 
attention especially considering the research that links compounds such as apigenin and 
naringenin to health promotion and disease prevention. Specifically, the data collected 
for this thesis add to the understanding of mechanisms involved in apigenin and 
naringenin’s chemoprotective ability. More research will need to be completed to better 
appreciate exactly how apigenin and naringenin impact biochemical pathways.  
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In addition to better understanding how these flavonoids impact a particular 
disease state, further examination of apigenin and naringenin should also be focused in 
areas of bioavailability, availability from dietary sources, dietary intake, biochemical 
pathway involvement, timing of intake for protection, and possible interactions with 
current disease treatments. With a larger accumulation of data in all areas related to 
apigenin and naringenin, we hope that someday there will be dietary recommendations 
for these flavonoids as well as other bioactive compounds.  
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NOMENCLATURE 
 
18S 18S ribosomal RNA 
Akt Protein kinase B 
AMPK 5' adenosine monophosphate-activated protein kinase 
ANOVA Analysis of variance 
AOM Azoxymethane 
Bax Bcl-2-like protein 4 
Bcl-2 B-cell lymphoma 2 
BrdU Bromodeoxyuridine 
CDK Cyclin-dependent kinase 
cDNA Complementary DNA 
CO2 Carbon dioxide 
Cox-2 Cyclooxygenase-2 or Prostaglandin-endoperoxide synthase 2 
Ct Cycle threshold 
DHA Docosahexaenoic acid 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DNase Deoxyribonuclease 
DSS Dextran sulfate sodium 
E2 Estradiol 
ERK 1/2 Extracellular-signal-regulated kinase 
 50 
 
 
ERα/β Estrogen receptor α or β 
FAM 6-carboxyfluorescein 
Fas TNF receptor superfamily, member 6 
FasL Fas ligand or cluster of differentiation 95 ligand (CD95L) 
FBS Fetal bovine serum 
HDAC Histone deacetylase 
HMACF High multiplicity crypt foci 
HRT Hormone replacement therapy 
IFN-γ Interferon γ 
IL Interleukin 
iNOS Inducible nitric oxide synthase 
LPS Lipopolysaccharides 
MAPK Mitogen-activated protein kinases 
MCT-1 Monocarboxylate transporter 1 (SLC16A1) 
MMP-9 Matrix metalloproteinase-9 
mp53 Mutated p53 
mRNA Messenger RNA 
mTOR Mechanistic target of rapamycin 
MyD88 Myeloid differentiation primary response gene (88) 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NIH National Institutes of Health 
Noxa Phorbol-12-myristate-13-acetate-induced protein 1 
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p21WAF1/CIP-1 Cyclin-dependent kinase inhibitor 1 
p53 Tumor suppressor p53 
p65 Transcription factor p65 or NF-κB p65 subunit 
pCMBS p-chloromercuribenzene sulfonate 
PCR Polymerase chain reaction 
PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase 
qRT-PCR Quantitative reverse transcription polymerase chain reaction 
RIN RNA integrity number 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RPMI Roswell Park Memorial Institute medium 
RT Reverse transcription 
SAS Statistical Analysis System 
SEM Standard error of the mean 
TIR Toll/Interleukin-1 receptor 
TLR Toll-like receptors 
TNFα Tumor necrosis factor α 
TRIF TIR-domain-containing adapter-inducing interferon-β 
US United States 
YAMC Young adult mouse colonocytes
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